Real-world evidence and its role in healthcare and life sciences

by Dr. Richard Swafford, Senior Principal Industry Strategist Data is integral to what the life sciences industry does. To establish and run clinical trials, companies depend on data about the disease state, the molecule they are working with, similar products on the market and, most crucially, the patient. Aside from advancing clinical trial recruitment, access […]

Reimagining patient centricity and healthcare practitioner engagement for 2020

by Satish Pandelenghat and Manjunath Shanabag The relationship between the life sciences industry and healthcare practitioners has changed dramatically in recent years. It wasn’t that long ago that sales reps visited each practice to provide information about new products. That changed in the late 1990s and early 2000s as information became more digital. Now what […]

4 considerations when choosing a solution for managing global regulatory submissions

by Dawn Waite and Sadia Ahmed There are so many balls in the air when managing global regulatory submissions that it’s all too easy to lose sight of the bigger picture. That picture really should be focusing on the portfolio, building your regulatory intelligence and strengthening your position in the market. But the day-to-day strain […]

Price alert: What state transparency laws will mean for pharma companies

by Manjunath Shanabag and Satish Nair Pharmaceutical and biotechnology companies are under pressure to manage their complex pricing environment in the wake of new state laws on price transparency. These laws were passed to deal with ongoing concerns about the growing cost of healthcare in the United States. In response, state governments have been taking steps […]

Life sciences 3.0: How an integrated environment can deliver healthier outcomes

By Sharad Khusal A new, connected dynamic is making its way into the life sciences and healthcare industries, shifting companies from a traditionally siloed approach to an integrated 3.0 environment. Here the emphasis is on a healthy outcomes ecosystem — one that spans nontraditional players such as IT, retailers and nonprofit organizations. At the heart […]

From R&D to health outcomes: Why a connected life sciences platform matters

by Sharad Khusal The life sciences business model is changing. In the past, companies typically worked with fewer partners, most often collaborating only with the physician, or indirectly, with patients. That later expanded to liaising with academia and the contract research organizations (CROs) directly affiliated with them. Today, those walls have come down and pharmaceutical […]

How digitization makes it easier to leverage real-world evidence across the life sciences value chain

by Gireesh Gaonkar The life sciences value chain — from R&D to manufacturing to marketing and sales — has long battled with addressing the challenges presented by silos, a complex network of global partners and affiliates, and as a result, inconsistent and disconnected ways to manage the large pool of data generated. But with the […]

La lección sobre IoT que ya deberíamos haber aprendido 

Hace unas semanas escribí sobre los pasos que las empresas deben iniciar para prepararse ante la llegada de Internet de las Cosas (IoT). Me centraba en la importancia de gestionar y analizar los datos generados, a partir de los dispositivos conectados. Pero conseguirlo depende de dos variables: conectividad y seguridad. Sin éstas, sus iniciativas IoT […]